Concepedia

Lingzhi Hong

LH

Statistics

Publications

34

Citations

2.4K

H-Index

23

Active since

2007

Affiliations

The University of Texas MD Anderson Cancer Center(Current)

Nanjing Medical University

Memorial Sloan Kettering Cancer Center

Dana-Farber Cancer Institute

Massachusetts General Hospital

Lingzhi Hong is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, oncology, and molecular oncology.

Publications per year

2007–2025

34

Publications

34

Structure-based classification predicts drug response in EGFR-mutant NSCLC

Jacqulyne Robichaux, Xiuning Le, R. S. K. Vijayan et al. · Nature · 2021 · 452 citations · Full text

Medicine, Molecular Genetics, Oncology +14

Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status

Biagio Ricciuti, Kathryn C. Arbour, Amir Vajdi et al. · Journal of Thoracic Oncology · 2021 · 367 citations · Full text

Medicine, Molecular Biology, Oncology +17

Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer

Marcelo V. Negrão, Ferdinandos Skoulidis, Meagan Montesion et al. · Journal for ImmunoTherapy of Cancer · 2021 · 292 citations · Full text

Medicine, Molecular Medicine, Oncology +17

Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLC

Lingzhi Hong, Marcelo V. Negrão, Seyedeh Dibaj et al. · Journal of Thoracic Oncology · 2020 · 192 citations · Full text

Medicine, Immunology, Oncology +17

Predicting benefit from immune checkpoint inhibitors in patients with non-small-cell lung cancer by CT-based ensemble deep learning: a retrospective study

Maliazurina B. Saad, Lingzhi Hong, Muhammad Aminu et al. · The Lancet Digital Health · 2023 · 109 citations · Full text

Medicine, Cancer Biology, Oncology +17

1–5 of 34